ClinicalTrials.gg
CompletedNCT06175273POINTUpdated Oct 8, 2026Results posted

Pediatric Oncology Nutrition Intervention Trial

A Phase 2/3 interventional study of Oral Nutrition Supplement and Tube Feed in Pediatric Cancer, Nutrition Related Cancer and Nutrition Aspect of Cancer, sponsored by Corey Hawes. Completed at 1 site in United States. Open to participants aged 2 Years to 19 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Corey Hawes · Phase 2/3, Interventional, and Supportive care

How we know

Updated Oct 8, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
2 Years to 19 Years
Sex
All
01

Study summary

Nearly 60% of pediatric patients diagnosed with cancer develop malnutrition caused by a combination of disease burden, side effects of chemotherapy, and the intensity of cancer treatment. These patients are known to have an increased risk of infection, treatment-related toxicity, inferior clinical outcomes, and increased risk of mortality. Malnutrition may progress to cancer cachexia, characterized by anorexia, increased inflammation, decreased fat, and decreased muscle mass with subsequent weight loss, which is associated with decreased overall survival.

The goal of the proposed research is to determine changes in body composition, weight status, and nutritional status between common nutrition interventions including oral nutrition supplements (ONS), appetite stimulants, and enteral nutrition (EN) among pediatric cancer patients. A secondary goal of this research is to utilize the findings to develop clinical nutrition guidelines for this patient population. The specific objective of the research proposed is to solve the lack of evidence to adequately treat nutritional deficits in the pediatric oncology population. Without this data, there is a lack of clinical consistency in the initiation and selection of appropriate nutrition interventions to provide a more definitive pathway of care. This study can help formulate a clinical guideline for this patient population before, during, and after treatment.

Read the detailed description

The investigators plan to enroll a minimum of 45 subjects between the ages of 2-18 years old, over the course of one year, including males and females of all ethnicities. The subject will be a newly diagnosed pediatric patient with cancer who will actively receive chemotherapy at UK Healthcare's Kentucky Children's Hospital (KCH).

All those who enroll will have a baseline ultrasound and biomarkers taken at enrollment. Participants will also receive 'standard of care' medical nutrition therapy (MNT) counseling at diagnosis for following a high protein/high-calorie diet. If any of the enrolled participants lose >10% of the diagnosis weight, the participants will then be randomized to receive (1) oral nutrition supplements, (2) age-appropriate appetite stimulants, or (3) enteral nutrition via a feeding tube. At the point of randomization, participants will receive another ultrasound and biomarkers. Those randomized will then receive additional ultrasounds and biomarkers at 1 month and 3 months after randomization. The remaining patients that have either weight maintenance or weight gain, will be utilized as a comparator group and will receive an ultrasound at 3 months and 6 months from enrollment/diagnosis. Each group will have a goal of at least 10 patients per group.

Those receiving ONS will be prescribed a standard ONS (1.0 kcal per mL) that will meet a minimum of 50% of estimated energy needs to promote weight gain but allow for continued regular dietary intakes. The ONS will be prescribed as 8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. Those receiving age-appropriate appetite stimulants will be provided either cyproheptadine or olanzapine. Subjects will be given cyproheptadine if the participants fall between the ages of 2-12 years of age and olanzapine if the participants are >12 years of age or older. Table 1 summarizes the medication dosage forms, initial and dose titration options, and precautions/contraindications of each appetite stimulant. Medication adjustments will be made within 2-4 weeks of initiation due to the variable peak effect times, and chemotherapy treatment plans dictating clinic follow-up. Those randomized to EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs to allow for continued regular dietary intakes during the day. After placement of a feeding tube, an abdominal x-ray will be obtained per hospital policy to confirm the appropriate placement of the feeding tube prior to use to ensure the safety of using said feeding tube.

Baseline demographics will be collected, including gender, age, diagnosis, QMLT ultrasound measurement, subjective global assessment (SGA) malnutrition risk, pediatric z-scores, and activity levels. Investigators will assess the subjects' nutritional intake, body composition via QMLT ultrasound, mid-upper arm circumference, pediatric z-scores (weight, length, and body mass index), biomarkers (leptin, IL-6, Lipid profiles, Cystatin-C, Vitamin D, and C-reactive protein), compliance and tolerance to nutrition intervention, physical activity, and clinical outcomes (rates of infection, number of hospital days for non-chemotherapy administration, number of clinic visits for non-chemotherapy administration, chemotherapy toxicity CTCAE grade, rate or relapse, and 1-year survival rates) at multiple time points throughout the study. Nutritional assessment will involve a 24-hour food recall which will be performed at diagnosis, randomization, and then every 1-2 weeks once randomized to an intervention. Weight loss and pediatric z-scores (weight-for-age, length-for-age, and BMI-for-age) will be assessed every 1-2 weeks throughout the study enrollment. Ultrasound assessment will be of the QMLT by measuring at the midpoint between the ASIS and the upper pole of the patella. The measurements will be taken bilaterally, three times, and averaged together for the final measurement. Ultrasound assessment will occur at enrollment when weight loss criteria are met for randomization, and then at 1 month and 3 months after randomization (or when the weight lost is regained).

Pediatric physical activity will be assessed every 1-2 weeks in combination with ultrasound measurements. Adherence and adverse effects to medications, tube feeds, or oral nutrition supplements will be assessed at each clinic visit. Biomarkers will be analyzed at randomization, 1 month, and 3 months after randomization.

Standard of care for patients are to receive MNT education at diagnosis. For those that lose weight, standard of care is to receive the nutrition interventions listed above (oral nutrition supplements, appetite stimulants, or enteral nutrition via feeding tube). The standard of care is to generally go from a least invasive to a more invasive approach. The research components of this study include being randomized to a nutrition intervention rather than a non-validated step-wise approach, the ultrasound measurements, and the biomarkers. These components are not considered standard of care and are research procedures. Baseline demographics will be collected, including gender, age, diagnosis, QMLT ultrasound measurement, subjective global assessment (SGA) malnutrition risk, pediatric z-scores, and activity levels. The team will assess the subjects' nutritional intake, body composition via QMLT ultrasound, mid-upper arm circumference, pediatric z-scores (weight, length, and body mass index), biomarkers (leptin, IL-6, Lipid profiles, Cystatin-C, Vitamin D, and C-reactive protein), compliance and tolerance to nutrition intervention, physical activity, and clinical outcomes (rates of infection, number of hospital days for non-chemotherapy administration, number of clinic visits for non-chemotherapy administration, chemotherapy toxicity CTCAE grade, rate or relapse, and 1-year survival rates) at multiple timepoints throughout the study. Nutritional assessment will involve a 24-hour food recall which will be performed at diagnosis, randomization, and then every 1-2 weeks once randomized to an intervention. Weight loss and pediatric z-scores (weight-for-age, length-for-age, and BMI-for-age) will be assessed every 1-2 weeks throughout the study enrollment. Ultrasound assessment will be of the QMLT by measuring at the midpoint between the ASIS and the upper pole of the patella, a total of 4 ultrasounds will be conducted during the study. The measurements will be taken bilaterally, three times, and averaged together for the final measurement. Ultrasound assessment will occur at enrollment when weight loss criteria are met for randomization, and then every 1-2 weeks for up to 8 weeks after randomization. Pediatric physical activity will be assessed every 1-2 weeks in combination with ultrasound measurements. Adherence and adverse effects to medications, tube feeds, or oral nutrition supplements will be assessed at each clinic visit.

Biomarkers will be analyzed at randomization, and weeks 4 and 8 after randomization. Additionally, measurements of resource utilization will be measured such as the number of hospital days for non-chemotherapy-related problems, the number of sick visits to the clinic, dietitian visits, infections, and rates of relapse or overall survival. Biomarkers will be drawn when the children are in the clinic for chemotherapy or lab work. The participants will already have their central venous line accessed by a qualified clinic RN and labs will be drawn at that time to ensure no extra harm to the patient. Additionally, all patients will have EMLA cream used to numb the area prior to having a clinic RN who is trained in accessing ports and has accessed the ports during previous clinic visits and will continue to do so throughout therapy.

02

Conditions studied

  • Pediatric Cancer
  • Nutrition Related Cancer
  • Nutrition Aspect of Cancer
  • Muscle Loss
  • Malnutrition, Child
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 20 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

This is the only study on the registry with Corey Hawes as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • New diagnosis of pediatric cancer

Exclusion criteria

Exclusion Criteria:

  • Current use or history of enteral nutrition, oral supplement, or orexigenic/anorectic use.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Control

    Standard of Care who have either weight gain, weight maintenance, or weight loss \<10%.

    Other: Standard of Care

  • Experimental
    Oral Nutrition Supplements

    Those receiving ONS will be prescribed a standard ONS (1.0 kcal per mL) that will meet a minimum of 50% of estimated energy needs to promote weight gain but allow for continued regular dietary intakes. The ONS will be prescribed as 8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs.

    Dietary Supplement: Oral Nutrition Supplement

  • Experimental
    Enteral Nutrition

    Those randomized to EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs to allow for continued regular dietary intakes during the day.

    Dietary Supplement: Tube Feed

  • Experimental
    Appetite Stimulants

    Those receiving age-appropriate appetite stimulants will be provided either cyproheptadine or olanzapine. Subjects will be given cyproheptadine if they fall between the ages of 2-12 years of age and olanzapine if they are \>12 years of age or older.

    Drug: Cyproheptadine · Drug: Olanzapine

Interventions

  • Dietary supplementOral Nutrition Supplement

    8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. The formula will equate to 1.0kcal/mL

  • Dietary supplementTube Feed

    EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs

  • 0.25mg/kg/d divided BID. May titrate by 4mg increments to a max of 12mg/day.

  • 2.5mg once a day (at night). May titrate by 2.5mg increments to max of 10mg/day

  • OtherStandard of Care

    Diet education on high protein, high calorie food consumption

06

What researchers measure

Primary outcomes

  1. Body Composition

    Change in quadriceps muscle layer thickness is measured by ultrasound and reported as change from baseline in centimeters.

    Time frame: Baseline, at 3 and 6 months after baseline

  2. Change in Body Composition Mid-Upper Arm

    Change in body composition will be measured by mid-upper arm circumference and will be measured in centimeters.

    Time frame: Baseline, at 3 and 6 months after baseline

Secondary outcomes

  1. Participants With Intervention Intolerances

    Intervention intolerances were assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) to determine toxicity grade.

    Time frame: Randomization through end of treatment (6 months)

  2. Change in Weight

    Weight will be measured in kilograms (kg).

    Time frame: Baseline, at 3 and 6 months after baseline

  3. Change in Body Mass Index (BMI)

    Body Mass Index (BMI) will be calculated using weight in pounds (lb) and height in inches (in).

    Time frame: Baseline, at 3 and 6 months after baseline

  4. Change in Biomarker IL-6

    IL-6 concentrations were measured from blood samples collected via central venous lines.

    Time frame: Baseline, at 3 and 6 months after baseline

  5. Change in Biomarker Leptin

    Leptin concentrations were measured from blood samples collected via central venous lines.

    Time frame: Baseline, at 3 and 6 months after baseline

  6. Change in Total Cholesterol

    Total cholesterol concentrations were measured from blood samples collected via central venous lines.

    Time frame: Baseline, at 3 and 6 months after baseline

  7. Change in Cystatin-C

    Cystatin-C concentrations were measured from blood samples collected from blood samples collected via central venous lines.

    Time frame: Baseline, at 3 and 6 months after baseline

  8. Change in Physical Activity

    Physical activity was assessed using the Lanksy Play-Performance Scale, a measure of Pediatric Functional Status based on parent descriptions of the child's activity and response to treatment. Scores ranges from 0-100, with higher scores indicating greater physical activity and functional status. Results are reported as the change from baseline to each follow-up assessment.

    Time frame: Baseline, at 3 and 6 months after baseline

  9. Tube Feeding Compliance

    Tube feeding compliance was assessed weekly by comparing the self-reported tube feeding volume (mL) with the prescribed tube feeding volume (mL). Results are reported as the change in volume relative to the prescribed amount.

    Time frame: From randomization through 3 months after randomization

  10. Oral Nutrition Supplements Compliance

    Compliance with prescribed oral nutrition supplements was assessed based on the amount of oral nutrition supplement (ONS) consumed compared with the prescribed amount. ONS was prescribed as 8 oz per dose at least once daily, depending on estimated nutrient needs. Percent compliance represents the amount of ONS consumed relative to the prescribed amount over the assessment period.

    Time frame: From randomization through 3 months after randomization

  11. Percentage of Participants Who Were Medication Compliant

    Medication compliance will be analyzed by self-reported weekly medication use during the period from randomization through 3 months after randomization. Overall compliance for the 3-month period will be calculated based on the number of days prescribed medications were taken as directed compared with the number of days medications were taken less than prescribed.

    Time frame: From randomization through 3 months after randomization

  12. Days Hospitalized for Nutrition-Related Issues

    The total number of days hospitalized for nutrition-related issues during the assessment period, as determined by review of the participant's medical record for hospitalizations related to nutritional status or nutrition-related complications.

    Time frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.

  13. Number of Clinic Visits for Nutrition-Related Issues

    The total number of clinic visits for nutrition-related issues during the assessment period, as determined by review of the participant's medical record for hospitalizations related to nutritional status or nutrition-related complications.

    Time frame: Baseline through 6 months for control group. From randomization through 3 months for intervention groups.

  14. Number of Participants With Malnutrition Diagnosis

    The number of participants with a malnutrition diagnosis during the assessment period, as documented in the study assessment. The data table reports the number of participants with a malnutrition diagnosis (yes responses).

    Time frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.

  15. Number of Participants With Relapse or Disease Progression

    The number of participants with relapse or disease progression during the assessment period. The data table reports the number of participants with relapse or disease progression (yes responses).

    Time frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.

  16. Number of Days That Cancer Treatment is Put on Hold

    The total number of days that cancer treatment was put on hold during the assessment period, as determined by review of the participant's medical record for hospitalizations related to nutritional status or nutrition-related complications.

    Time frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.

  17. CTCAE Toxicity Grade

    Treatment-related toxicities were assessed using the Common Terminology Criteria for Adverse Events (CTCAE) grading scale (Grades 1-4). Higher grades indicate more severe toxicity. All participants were assessed for treatment-related toxicities during the assessment period. No participants experienced treatment-related toxicities.

    Time frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.

  18. Cancer Diagnosis Type

    These measurements will include the diagnosis type (cancer type).

    Time frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.

  19. Biomarker Vitamin D Level

    Vitamin D levels (ng/mL) will be measured from blood samples collected via central venous lines at each study assessment.

    Time frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)

  20. Triglyceride Level

    Triglyceride levels (mg/dL) will be measured from blood samples collected via central venous lines at each study assessment.

    Time frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)

  21. Biomarker: Low-Density Lipoprotein (LDL) Level

    Low Density Lipoprotein (LDL) levels (mg/dL) will be measured from blood samples collected via central venous lines at each study assessment.

    Time frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)

  22. Biomarker: High-Density Lipoprotein (HDL) Level

    High-Density Lipoprotein (HDL) levels (mg/dL) will be measured from blood samples collected via central venous lines at each study assessment.

    Time frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)

  23. Biomarker: C-Reactive Protein (CRP) Level

    C-Reactive Protein (CRP) Level (mg/L) will be measured via central venous lines at each study assessment.

    Time frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)

07

Results

Posted Oct 8, 2026

Participant flow

Participant flow — Overall Study
MilestoneControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Started17102
Completed15101
Not completed2001
Withdrew: Lost to follow-up1001
Withdrew: Change in medical management1000

Outcome measures

PrimaryBody Composition

Change in quadriceps muscle layer thickness is measured by ultrasound and reported as change from baseline in centimeters.

Time frame:
Baseline, at 3 and 6 months after baseline
Reported as:
Mean · Centimeters
Body Composition
CentimetersControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Mean Baseline to 3 Months-0.12596 ± 1.0417-0.5450—-0.6750
Mean Baseline to 6 Months (End of Treatment)-0.46722 ± 0.897580.185—-0.290
PrimaryChange in Body Composition Mid-Upper Arm

Change in body composition will be measured by mid-upper arm circumference and will be measured in centimeters.

Time frame:
Baseline, at 3 and 6 months after baseline
Reported as:
Mean · Centimeters
Change in Body Composition Mid-Upper Arm
CentimetersControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months-0.352 ± 0.2850—-0.30
Baseline to 6 Months (End of Treatment)-0.605 ± 0.3920.91—1.29
SecondaryParticipants With Intervention Intolerances

Intervention intolerances were assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) to determine toxicity grade.

Time frame:
Randomization through end of treatment (6 months)
Reported as:
Count of participants · Participants
Participants With Intervention Intolerances
ParticipantsControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Participants With Intervention Intolerances0000
SecondaryChange in Weight

Weight will be measured in kilograms (kg).

Time frame:
Baseline, at 3 and 6 months after baseline
Reported as:
Mean · Kilograms
Change in Weight
KilogramsControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months-2.991 ± 1.378-4.1—-1.29
Baseline to 6 Months (End of Treatment)-4.782 ± 1.2078.8—2.7
SecondaryChange in Body Mass Index (BMI)

Body Mass Index (BMI) will be calculated using weight in pounds (lb) and height in inches (in).

Time frame:
Baseline, at 3 and 6 months after baseline
Reported as:
Mean · lbs/inches^2
Change in Body Mass Index (BMI)
lbs/inches^2ControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months-1.064 ± 0.526-1.6—-1.93
Baseline to 6 Months (End of Treatment)-1.982 ± 0.3781.8—4.3
SecondaryChange in Biomarker IL-6

IL-6 concentrations were measured from blood samples collected via central venous lines.

Time frame:
Baseline, at 3 and 6 months after baseline
Reported as:
Mean · pg/mL
Change in Biomarker IL-6
pg/mLControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months-8.119 ± 6.260-0.5—39.71
Baseline to 6 Months (End of Treatment)-5.856 ± 7.764-0.9—0
SecondaryChange in Biomarker Leptin

Leptin concentrations were measured from blood samples collected via central venous lines.

Time frame:
Baseline, at 3 and 6 months after baseline
Reported as:
Mean · ng/mL
Change in Biomarker Leptin
ng/mLControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months0.66 ± 0.4461.66—2.09
Baseline to 6 Months (End of Treatment)-0.644 ± 0.4310.74—1.01
SecondaryChange in Total Cholesterol

Total cholesterol concentrations were measured from blood samples collected via central venous lines.

Time frame:
Baseline, at 3 and 6 months after baseline
Reported as:
Mean · mg/dL
Change in Total Cholesterol
mg/dLControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months51.125 ± 14.168-3.0—24.0
Baseline to 6 Months (End of Treatment)51.750 ± 11.7502.0—-1.0
SecondaryChange in Cystatin-C

Cystatin-C concentrations were measured from blood samples collected from blood samples collected via central venous lines.

Time frame:
Baseline, at 3 and 6 months after baseline
Reported as:
Mean · mg/L
Change in Cystatin-C
mg/LControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months-1.030 ± 3.151.18—114.57
Baseline to 6 Months-0.980 ± 2.1117.06—-5.75
SecondaryChange in Physical Activity

Physical activity was assessed using the Lanksy Play-Performance Scale, a measure of Pediatric Functional Status based on parent descriptions of the child's activity and response to treatment. Scores ranges from 0-100, with higher scores indicating greater physical activity and functional status. Results are reported as the change from baseline to each follow-up assessment.

Time frame:
Baseline, at 3 and 6 months after baseline
Reported as:
Mean · score on a scale
Change in Physical Activity
score on a scaleControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months5.445 ± 2.073-30—0
Baseline to 6 Months (End of Treatment)3.636 ± 1.521-10—0
SecondaryTube Feeding Compliance

Tube feeding compliance was assessed weekly by comparing the self-reported tube feeding volume (mL) with the prescribed tube feeding volume (mL). Results are reported as the change in volume relative to the prescribed amount.

Time frame:
From randomization through 3 months after randomization
Reported as:
Count of participants · Participants
Tube Feeding Compliance
ParticipantsControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Tube Feeding Compliance00—0
SecondaryOral Nutrition Supplements Compliance

Compliance with prescribed oral nutrition supplements was assessed based on the amount of oral nutrition supplement (ONS) consumed compared with the prescribed amount. ONS was prescribed as 8 oz per dose at least once daily, depending on estimated nutrient needs. Percent compliance represents the amount of ONS consumed relative to the prescribed amount over the assessment period.

Time frame:
From randomization through 3 months after randomization
Reported as:
Mean · Percentage of Prescribed ONS Consumed
Oral Nutrition Supplements Compliance
Percentage of Prescribed ONS ConsumedControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Oral Nutrition Supplements Compliance0 (0 to 0)90 (90 to 90)—0 (0 to 0)
SecondaryPercentage of Participants Who Were Medication Compliant

Medication compliance will be analyzed by self-reported weekly medication use during the period from randomization through 3 months after randomization. Overall compliance for the 3-month period will be calculated based on the number of days prescribed medications were taken as directed compared with the number of days medications were taken less than prescribed.

Time frame:
From randomization through 3 months after randomization
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Medication Compliant
percentage of participantsControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Percentage of Participants Who Were Medication Compliant00—100
SecondaryDays Hospitalized for Nutrition-Related Issues

The total number of days hospitalized for nutrition-related issues during the assessment period, as determined by review of the participant's medical record for hospitalizations related to nutritional status or nutrition-related complications.

Time frame:
Baseline through 6 months for control group. Randomization through 3 months for intervention group.
Reported as:
Mean · Days
Days Hospitalized for Nutrition-Related Issues
DaysControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Days Hospitalized for Nutrition-Related Issues0.54 ± 1.9410 ± 0—0 ± 0
SecondaryNumber of Clinic Visits for Nutrition-Related Issues

The total number of clinic visits for nutrition-related issues during the assessment period, as determined by review of the participant's medical record for hospitalizations related to nutritional status or nutrition-related complications.

Time frame:
Baseline through 6 months for control group. From randomization through 3 months for intervention groups.
Reported as:
Mean · Clinic Visits
Number of Clinic Visits for Nutrition-Related Issues
Clinic VisitsControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Number of Clinic Visits for Nutrition-Related Issues1 ± 3.60616—21
SecondaryNumber of Participants With Malnutrition Diagnosis

The number of participants with a malnutrition diagnosis during the assessment period, as documented in the study assessment. The data table reports the number of participants with a malnutrition diagnosis (yes responses).

Time frame:
Baseline through 6 months for control group. Randomization through 3 months for intervention group.
Reported as:
Count of participants · Participants
Number of Participants With Malnutrition Diagnosis
ParticipantsControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Number of Participants With Malnutrition Diagnosis1101
SecondaryNumber of Participants With Relapse or Disease Progression

The number of participants with relapse or disease progression during the assessment period. The data table reports the number of participants with relapse or disease progression (yes responses).

Time frame:
Baseline through 6 months for control group. Randomization through 3 months for intervention group.
Reported as:
Count of participants · Participants
Number of Participants With Relapse or Disease Progression
ParticipantsControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Number of Participants With Relapse or Disease Progression00—0
SecondaryNumber of Days That Cancer Treatment is Put on Hold

The total number of days that cancer treatment was put on hold during the assessment period, as determined by review of the participant's medical record for hospitalizations related to nutritional status or nutrition-related complications.

Time frame:
Baseline through 6 months for control group. Randomization through 3 months for intervention group.
Reported as:
Mean · Days
Number of Days That Cancer Treatment is Put on Hold
DaysControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Number of Days That Cancer Treatment is Put on Hold16.38 ± 26.22514—7
SecondaryCTCAE Toxicity Grade

Treatment-related toxicities were assessed using the Common Terminology Criteria for Adverse Events (CTCAE) grading scale (Grades 1-4). Higher grades indicate more severe toxicity. All participants were assessed for treatment-related toxicities during the assessment period. No participants experienced treatment-related toxicities.

Time frame:
Baseline through 6 months for control group. Randomization through 3 months for intervention group.
Reported as:
Number · participants
CTCAE Toxicity Grade
participantsControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
CTCAE Toxicity Grade00—0
SecondaryCancer Diagnosis Type

These measurements will include the diagnosis type (cancer type).

Time frame:
Baseline through 6 months for control group. Randomization through 3 months for intervention group.
Reported as:
Count of participants · Participants
Cancer Diagnosis Type
ParticipantsControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Hodgkin's Lymphoma2000
T-Cell ALL1000
B-Cell ALL4000
CNS Tumor2000
Wilm's Tumor2000
Acute Myeloid Leukemia3000
Ewing's Sarcoma1000
Non-Hodgkin's Lymphoma0100
Hepatoblastoma0001
SecondaryBiomarker Vitamin D Level

Vitamin D levels (ng/mL) will be measured from blood samples collected via central venous lines at each study assessment.

Time frame:
Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
Reported as:
Mean · ng/mL
Biomarker Vitamin D Level
ng/mLControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months-0.975 ± 2.192-5.5—-10.5
Baseline to 6 Months (End of Treatment)-1.088 ± 2.30826.3—4.0
SecondaryTriglyceride Level

Triglyceride levels (mg/dL) will be measured from blood samples collected via central venous lines at each study assessment.

Time frame:
Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
Reported as:
Mean · mg/dL
Triglyceride Level
mg/dLControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months93.125 ± 46.5236.0—-10.0
Baseline to 6 Months (End of Treatment)155.125 ± 23.77513.0—115.0
SecondaryBiomarker: Low-Density Lipoprotein (LDL) Level

Low Density Lipoprotein (LDL) levels (mg/dL) will be measured from blood samples collected via central venous lines at each study assessment.

Time frame:
Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
Reported as:
Mean · mg/dL
Biomarker: Low-Density Lipoprotein (LDL) Level
mg/dLControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months43.125 ± 12.8038.0—30.0
Baseline to 6 Months (End of Treatment)39.875 ± 11.47010—-10
SecondaryBiomarker: High-Density Lipoprotein (HDL) Level

High-Density Lipoprotein (HDL) levels (mg/dL) will be measured from blood samples collected via central venous lines at each study assessment.

Time frame:
Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
Reported as:
Mean · mg/dL
Biomarker: High-Density Lipoprotein (HDL) Level
mg/dLControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months-9.0 ± 7.464-3.0—-4.0
Baseline to 6 Months (End of Treatment)-15.00 ± 5.898-1.0—-9.0
SecondaryBiomarker: C-Reactive Protein (CRP) Level

C-Reactive Protein (CRP) Level (mg/L) will be measured via central venous lines at each study assessment.

Time frame:
Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
Reported as:
Mean · mg/L
Biomarker: C-Reactive Protein (CRP) Level
mg/LControlOral Nutrition SupplementsEnteral NutritionAppetite Stimulants
Baseline to 3 Months-2.530 ± 3.0834.52—-6.59
Baseline to 6 Months (End of Treatment)-3.356 ± 2.5816.07—-4.69

Adverse events

Collected over 6 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control0/15 (0%)0/15 (0%)0/15 (0%)
Oral Nutrition Supplements0/1 (0%)0/1 (0%)0/1 (0%)
Enteral Nutrition———
Appetite Stimulants0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

There were no participants enrolled in the Enteral Nutrition Arm. Participants were randomized at study enrollment. Oral Nutrition Supplements, Enteral Nutrition, and Appetite Stimulants represent protocol-defined nutrition interventions that were implemented after randomization only if participants met prespecified clinical criteria (\>10% weight loss/insufficient energy intake). No participants were enrolled directly into these intervention groups.

Age, Continuous
Age, Continuous(years)ControlOral Nutrition SupplementsEnteral NutritionAppetite StimulantsTotal
Mean10.15 ± 4.6168—129.82 ± 4.246
Sex: Female, Male
Sex: Female, Male(Participants)ControlOral Nutrition SupplementsEnteral NutritionAppetite StimulantsTotal
Female51—17
Male100—010
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ControlOral Nutrition SupplementsEnteral NutritionAppetite StimulantsTotal
Hispanic or Latino00—00
Not Hispanic or Latino151—117
Unknown or Not Reported00—00
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ControlOral Nutrition SupplementsEnteral NutritionAppetite StimulantsTotal
American Indian or Alaska Native00—00
Asian00—00
Native Hawaiian or Other Pacific Islander00—00
Black or African American10—01
White141—116
More than one race00—00
Unknown or Not Reported00—00
Region of Enrollment
Region of Enrollment(participants)ControlOral Nutrition SupplementsEnteral NutritionAppetite StimulantsTotal
United States151—117
08

Study locations

1 site
  • University of Kentucky
    Lexington, Kentucky 40536, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Aug 2025, 18 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 47 phase 2/3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 90. This study's 18 months is below that.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2023
First posted
Dec 18, 2023
StartActual
Jan 31, 2024
Primary completionActual
Aug 4, 2025
CompletionActual
Aug 4, 2025
Results first posted
Oct 8, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 8, 2026
Enrollment
19→20
Oct 8, 2026
Primary outcomes
1 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • ChangedBefore Body CompositionNow Change in Body Composition Mid-Upper ArmTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months. → Baseline, at 3 and 6 months after baseline
  • Time frameBody CompositionBaseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months. → Baseline, at 3 and 6 months after baseline
  • DescriptionBody Composition: how it is measured was reworded
Oct 8, 2026
Secondary outcomes
6 edited, 17 added, 7 removed, 5 more
What changed in the outcomes
  • EditedChange in weightWeightTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months. → Baseline, at 3 and 6 months after baseline
  • EditedChange in Body Mass Index (BMI)Time frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months. → Baseline, at 3 and 6 months after baseline
  • EditedChange in Physical ActivityTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months. → Baseline, at 3 and 6 months after baseline
  • EditedTube feeding complianceFeeding ComplianceTime frame: Those randomized will receive measurements at randomization and 1 & 3 months. → From randomization through 3 months after randomization
  • EditedOral nutrition supplements complianceNutrition Supplements ComplianceTime frame: Those randomized will receive measurements at randomization and 1 & 3 months. → From randomization through 3 months after randomization
  • ChangedBefore Clinical measuresNow Cancer Diagnosis TypeTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months. → Baseline through 6 months for control group. Randomization through 3 months for intervention group.
  • AddedParticipants With Intervention IntolerancesTime frame: Randomization through end of treatment (6 months)
  • AddedChange in Biomarker IL-6Time frame: Baseline, at 3 and 6 months after baseline
  • AddedChange in Biomarker LeptinTime frame: Baseline, at 3 and 6 months after baseline
  • AddedChange in Total CholesterolTime frame: Baseline, at 3 and 6 months after baseline
  • AddedChange in Cystatin-CTime frame: Baseline, at 3 and 6 months after baseline
  • AddedPercentage of Participants Who Were Medication CompliantTime frame: From randomization through 3 months after randomization
  • AddedDays Hospitalized for Nutrition-Related IssuesTime frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
  • AddedNumber of Clinic Visits for Nutrition-Related IssuesTime frame: Baseline through 6 months for control group. From randomization through 3 months for intervention groups.
  • AddedNumber of Participants With Malnutrition DiagnosisTime frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
  • AddedNumber of Participants With Relapse or Disease ProgressionTime frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
  • AddedNumber of Days That Cancer Treatment is Put on HoldTime frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
  • AddedCTCAE Toxicity GradeTime frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
  • AddedBiomarker Vitamin D LevelTime frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
  • AddedTriglyceride LevelTime frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
  • AddedBiomarker: Low-Density Lipoprotein (LDL) LevelTime frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
  • AddedBiomarker: High-Density Lipoprotein (HDL) LevelTime frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
  • AddedBiomarker: C-Reactive Protein (CRP) LevelTime frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
  • RemovedIntolerances to interventionsTime frame: Those randomized to a treatment group, will receive measurements at randomization and 1 & 3 months.
  • RemovedBiomarkersTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months.
  • RemovedBiomarkersTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months.
  • RemovedBiomarkersTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months.
  • RemovedBiomarkersTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months.
  • RemovedMedication complianceTime frame: Those randomized will receive measurements at randomization and 1 & 3 months.
  • RemovedClinical measuresTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months.
  • …and 5 more, on the record history on ClinicalTrials.gov ↗
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Results posted
    Enrollment 19→20
    Primary outcomes 1 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • ChangedBefore Body CompositionNow Change in Body Composition Mid-Upper ArmTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months. → Baseline, at 3 and 6 months after baseline
    • Time frameBody CompositionBaseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months. → Baseline, at 3 and 6 months after baseline
    • DescriptionBody Composition: how it is measured was reworded
    Secondary outcomes 6 edited, 17 added, 7 removed, 5 more
    What changed in the outcomes
    • EditedChange in weightWeightTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months. → Baseline, at 3 and 6 months after baseline
    • EditedChange in Body Mass Index (BMI)Time frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months. → Baseline, at 3 and 6 months after baseline
    • EditedChange in Physical ActivityTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months. → Baseline, at 3 and 6 months after baseline
    • EditedTube feeding complianceFeeding ComplianceTime frame: Those randomized will receive measurements at randomization and 1 & 3 months. → From randomization through 3 months after randomization
    • EditedOral nutrition supplements complianceNutrition Supplements ComplianceTime frame: Those randomized will receive measurements at randomization and 1 & 3 months. → From randomization through 3 months after randomization
    • ChangedBefore Clinical measuresNow Cancer Diagnosis TypeTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months. → Baseline through 6 months for control group. Randomization through 3 months for intervention group.
    • AddedParticipants With Intervention IntolerancesTime frame: Randomization through end of treatment (6 months)
    • AddedChange in Biomarker IL-6Time frame: Baseline, at 3 and 6 months after baseline
    • AddedChange in Biomarker LeptinTime frame: Baseline, at 3 and 6 months after baseline
    • AddedChange in Total CholesterolTime frame: Baseline, at 3 and 6 months after baseline
    • AddedChange in Cystatin-CTime frame: Baseline, at 3 and 6 months after baseline
    • AddedPercentage of Participants Who Were Medication CompliantTime frame: From randomization through 3 months after randomization
    • AddedDays Hospitalized for Nutrition-Related IssuesTime frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
    • AddedNumber of Clinic Visits for Nutrition-Related IssuesTime frame: Baseline through 6 months for control group. From randomization through 3 months for intervention groups.
    • AddedNumber of Participants With Malnutrition DiagnosisTime frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
    • AddedNumber of Participants With Relapse or Disease ProgressionTime frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
    • AddedNumber of Days That Cancer Treatment is Put on HoldTime frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
    • AddedCTCAE Toxicity GradeTime frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
    • AddedBiomarker Vitamin D LevelTime frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
    • AddedTriglyceride LevelTime frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
    • AddedBiomarker: Low-Density Lipoprotein (LDL) LevelTime frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
    • AddedBiomarker: High-Density Lipoprotein (HDL) LevelTime frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
    • AddedBiomarker: C-Reactive Protein (CRP) LevelTime frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
    • RemovedIntolerances to interventionsTime frame: Those randomized to a treatment group, will receive measurements at randomization and 1 & 3 months.
    • RemovedBiomarkersTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months.
    • RemovedBiomarkersTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months.
    • RemovedBiomarkersTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months.
    • RemovedBiomarkersTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months.
    • RemovedMedication complianceTime frame: Those randomized will receive measurements at randomization and 1 & 3 months.
    • RemovedClinical measuresTime frame: Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months.
    • …and 5 more, on the record history on ClinicalTrials.gov ↗
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06175273
Lead sponsor
Corey Hawes
Responsible party
Corey Hawes (Clinical Nutrition Professor, University of Kentucky) — Sponsor-investigator
First posted
Dec 18, 2023
Start date
Jan 31, 2024
Primary completion
Aug 4, 2025
Completion
Aug 4, 2025
Results posted
Oct 8, 2026
Last update
Oct 8, 2026

Study contacts

Corey J Hawes, DCN, RD, CSO, CNSC, LD
principal investigator · University of Kentucky, Kentucky Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyproheptadine · Olanzapine

Start the discussion